Tirzepatide (MOUNJARO) is a once-weekly subcutaneous injectable agent first authorized for T2DM and later extended to the management of obesity or overweight with at least one weight-related comorbidity, thereby aligning its therapeutic scope with subcutaneous liraglutide and semaglutide [34,35,36]
Heres what it does: Kidney Health Protection Studies show the medication cuts kidney problems by 22%
GLP-1 medications are not recommended for use during pregnancy
Structured meal planning , consistent exercise, adequate sleep, and stress management remain the foundation of weight management even when using the most effective medications available
Because the combination of therapies with
Obesity is the root cause of many chronic diseases including cardiovascular disease, the number one killer, but also diabetes, liver and kidney disease